2 dependable shares to retire on

Bilaal Mohamed reveals two perfect picks for long-term income investors.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In common with many other pharmaceutical giants AstraZeneca (LSE: AZN) has suffered at the hands of generic competition in recent years as patents expire on some of their more important drugs. As a result, both sales revenue and underlying earnings have been in steep decline. But the FTSE 100 drugs giant has continued to reward its shareholders handsomely, managing to maintain its annual dividend payouts at 280¢ per share. But can we rely on this level of income forever?

Turning point

Astra’s best-selling anti-cholesterol pill Crestor is now facing tough generic competition, with sales plunging 57% in the US during 2016, and contributing to an overall sales decline in the US of 22% to $7,365m. Europe performed much better with a decline of just 3% to $5,064m. Another of Astra’s blockbuster drugs Nexium, used for the treatment of heartburn, has also suffered with a sales decline of 39% in the US, reflecting lower demand and inventory de-stocking following the loss of exclusivity in 2015.

Although disappointing, Astra’s performance during 2016 was broadly in line with expectations, with 2017 possibly a defining year for the multinational pharmaceuticals giant. Crestor represents the last anticipated blockbuster patent expiry ahead of significant late-stage pipeline news, which could lead to an important turning point for the drugmaker.

Promising pipeline

The company has a promising pipeline of immuno-oncology and targeted treatments, and this year has the opportunity to launch several life-changing medicines for cancer, respiratory and metabolic diseases. This could be an exciting time for Astra and its shareholders as it rapidly approaches the turning point for its anticipated return to long-term growth.

Shareholders should perhaps be grateful that Astra has managed to maintain its dividend while facing tough challenges over the past few years. They could well reap the rewards for their patience in the long run with the company poised to return to growth in the not-too-distant future. The shares trades on an undemanding P/E ratio of 15 for the current year, and support a healthy dividend yield of 4.8%.

Buy and hold

For income seekers who require a little more certainty with regards to the outlook, perhaps a better pick would be Astra’s closest peer GlaxoSmithKline (LSE: GSK). Its 2016 performance certainly made better reading than that of its rival, with group sales rising by 17% to £27.9bn, equivalent to 6% on a constant currency basis. Perhaps most encouraging was the news that new product sales had more than doubled to £4.5bn, driven by strong performances from HIV drugs, respiratory treatments and meningitis vaccines.

The City is expecting the Brentford-based drugs giant to hit £30bn in revenues by the end of the year, while boosting underlying earnings to £5.5bn. Glaxo has long been a favourite with buy-and-hold investors, and continues to reward shareholders with generous payouts, its shares currently offering a solid yield of 4.9%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »